Argenta Discovery announces collaboration with Antisoma
Argenta Discovery Ltd. announced that it entered into a fee-for-service collaboration with Antisoma plc
| 1 min read
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.
Here are some related topics that may interest you:
LONDON—Argenta Discovery Ltd., the pharmaceutical R&D group, announced that it entered into a fee-for-service collaboration with Antisoma plc. Under the terms of the agreement, scientists from the two organizations will work together to develop improved molecules for Antisoma's program of telomere targeting agents (TTAs). Antisoma will utilize Argenta's expertise in medicinal chemistry, computer-aided drug design, molecular biology, biochemistry, assay development and in vitro screening, during the course of the collaboration.
"Antisoma's decision to work with us confirms our contract research team's experience in undertaking integrated, oncology-focused programs, and underlines Argenta's ongoing commitment to providing first-class contract R&D services to leading organizations in the pharmaceutical industry," says Dr. Christopher Ashton, Argenta's CEO.
